Bath & Body Works Surges on Stock Recommendation; Klarna Drops on Guidance | Stock Movers
On this episode of Stock Movers: - Shares of Klarna (KLAR) plunged in premarket trading after the payments company reported full year revenue and gross merchandise value guidance that missed expectations. The company cited foreign exchange pressures and volumes in Germany, even as it reported a profit beat for the second straight quarter. - Shares of Amylyx Pharmaceuticals (AMLX) extended its…
Klarna's stock took a nosedive in premarket trading following the payments company's announcement that it missed revenue and gross merchandise value expectations for the full year. Despite reporting a profit beat for the second consecutive quarter, the company attributed the shortfall to foreign exchange pressures and lower volumes in Germany.
Amylyx Pharmaceuticals (AMLX) experienced a significant rally in the early trading session, surging as much as 54%. The drug developer reported that a late-stage trial of its experimental drug met its primary endpoint in treating patients who experience low blood sugar levels after bariatric surgery.
Bath & Body Works (BBWI) saw a surge in its stock price ahead of the opening bell as Citi raised its recommendation on the stock from neutral to buy. Analyst Paul Lejuez cited a favorable risk/reward outlook in his note. The company is scheduled to release earnings next week.
Written by urgent.news from Bloomberg's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
